CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

A large electronic health record study suggests that difficulty recognizing painless blood in urine may delay diagnosis and worsen long-term survival for bladder cancer patients with color vision ...

May 14 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a ‌surgery, showed significantly improved survival ...

SUZHOU, China, June 1, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented ...

Also Read: ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug Specific key efficacy findings from cohort B (N=80) of the Phase 2/3 open-label, single-arm ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...

Raise awareness this May for bladder cancer, its symptoms, and the importance of early detection to save lives.

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...

People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...